Janus kinases (JAKs) have been targeted therapeutically in SAVI (10, 14, 34), and IFN receptors have preferential requirements for specific JAK proteins, including JAK1, JAK2, and TYK2 (35). The gene discussed is JAK2; the disease is STING-associated vasculopathy with onset in infancy.